[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555709":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":227,"collaborators":30,"id":229,"slug":230,"hasResults":231,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":30,"eligibilityCriteria":235,"healthyVolunteers":231,"sex":236,"minAge":237,"maxAge":30,"enrollmentInfo":238,"targetDuration":30,"studyType":241,"phases":242,"briefSummary":244,"conditions":245,"keywords":30,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},{"fullName":5,"class":6},"Context Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CTIM-76","EXPERIMENTAL","Phase 1a: Dose Escalation-each dose cohort will assess toxicity 28 days following the first dose of CTIM76; anticipate a total of 9 dose cohorts.\n\nPhase 1b: Dose Expansion - approximately 80 participants will be evaluated at a minimum of 2 dose levels and\u002For dosing schedules of CTIM-76",[13],"Drug: CTIM-76",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","CLDN6 bispecific Antibody administered weekly (Day 1, 8, 15 and 22) of a 28-day treatment cycle until disease progression.",[9],[20],"CTIM-76 Claudin 6 bispecific Antibody",[22],{"name":23,"affiliation":5,"role":24},"Karen Chagin, MD","STUDY_CHAIR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Context Clinical Development","CONTACT","267-225-7416",null,"cntx-ctim76-101@contexttherapeutics.com",[33,53,64,79,94,105,118,133,143,158,168,183,198,213],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"University of Arkansas Winthrop P. Rockefeller Cancer Institute","RECRUITING","Little Rock","Arkansas","72205","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-92.28959,34.74648,{"lat":45,"lon":44},[48],{"name":49,"role":28,"phone":50,"phoneExt":51,"email":52},"Maroof Zafar","501-686-8274","24576","MKZafar@uams.edu",{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":39,"countryCode":40,"cosmosGeoPoint":59,"geoPoint":63,"contacts":30},"Precision NextGen Oncology & Research Center","WITHDRAWN","Beverly Hills","California","90212",{"type":42,"coordinates":60},[61,62],-118.40036,34.07362,{"lat":62,"lon":61},{"facility":65,"status":35,"city":66,"state":67,"zip":68,"country":39,"countryCode":40,"cosmosGeoPoint":69,"geoPoint":73,"contacts":74},"SCRI at Denver Health","Denver","Colorado","80218",{"type":42,"coordinates":70},[71,72],-104.9847,39.73915,{"lat":72,"lon":71},[75],{"name":76,"role":28,"phone":77,"phoneExt":30,"email":78},"Front Desk","720-754-2610","CANN.DDUDenverGeneral@SarahCannon.com",{"facility":80,"status":35,"city":81,"state":82,"zip":83,"country":39,"countryCode":40,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Dana-Farber Cancer Institute","Boston","Massachusetts","02215",{"type":42,"coordinates":85},[86,87],-71.05977,42.35843,{"lat":87,"lon":86},[90],{"name":91,"role":28,"phone":92,"phoneExt":30,"email":93},"Rebecca Porter, MD","(877) 338-7425","Rebecca_Porter@DFCI.HARVARD.EDU",{"facility":95,"status":96,"city":97,"state":98,"zip":99,"country":39,"countryCode":40,"cosmosGeoPoint":100,"geoPoint":104,"contacts":30},"John Theurer Cancer Center","TERMINATED","Hackensack","New Jersey","07601",{"type":42,"coordinates":101},[102,103],-74.04347,40.88593,{"lat":103,"lon":102},{"facility":106,"status":35,"city":107,"state":107,"zip":108,"country":39,"countryCode":40,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"Memorial Sloan Kettering Cancer Center","New York","10021",{"type":42,"coordinates":110},[111,112],-74.00597,40.71427,{"lat":112,"lon":111},[115],{"name":116,"role":28,"phone":30,"phoneExt":30,"email":117},"Roisin O'Cearbhaill, MD","ocearbhr@mskcc.org",{"facility":119,"status":35,"city":120,"state":121,"zip":122,"country":39,"countryCode":40,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Duke Cancer Institute","Durham","North Carolina","27710",{"type":42,"coordinates":124},[125,126],-78.89862,35.99403,{"lat":126,"lon":125},[129],{"name":130,"role":28,"phone":131,"phoneExt":30,"email":132},"Duke Cancer Institute - Phase I and Immunotherapy Trials","919-684-6342","Phase1andImmunotherapyreferrals@duke.edu",{"facility":134,"status":55,"city":135,"state":136,"zip":137,"country":39,"countryCode":40,"cosmosGeoPoint":138,"geoPoint":142,"contacts":30},"Gabrail Cancer Center","Canton","Ohio","44718",{"type":42,"coordinates":139},[140,141],-81.37845,40.79895,{"lat":141,"lon":140},{"facility":144,"status":35,"city":145,"state":146,"zip":147,"country":39,"countryCode":40,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Providence Cancer Institute of Oregon","Portland","Oregon","97213",{"type":42,"coordinates":149},[150,151],-122.67621,45.52345,{"lat":151,"lon":150},[154],{"name":155,"role":28,"phone":156,"phoneExt":30,"email":157},"Christopher Darus, MD","503-215-2075","CanRsrchStudies@Providence.org",{"facility":159,"status":55,"city":160,"state":161,"zip":162,"country":39,"countryCode":40,"cosmosGeoPoint":163,"geoPoint":167,"contacts":30},"Fox Chase Cancer Center","Philadelphia","Pennsylvania","19111",{"type":42,"coordinates":164},[165,166],-75.16362,39.95238,{"lat":166,"lon":165},{"facility":169,"status":35,"city":170,"state":171,"zip":172,"country":39,"countryCode":40,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Women & Infants Hospital of Rhode Island","Providence","Rhode Island","02905",{"type":42,"coordinates":174},[175,176],-71.41283,41.82399,{"lat":176,"lon":175},[179],{"name":180,"role":28,"phone":181,"phoneExt":30,"email":182},"Mary Dionne","401-453-8181","MDionne@WIHRI.org",{"facility":184,"status":35,"city":185,"state":186,"zip":187,"country":39,"countryCode":40,"cosmosGeoPoint":188,"geoPoint":192,"contacts":193},"Vanderbilt-Ingram Cancer Center","Nashville","Tennessee","37232",{"type":42,"coordinates":189},[190,191],-86.78444,36.16589,{"lat":191,"lon":190},[194],{"name":195,"role":28,"phone":196,"phoneExt":30,"email":197},"Vanderbilt-Ingram Cancer Center Clinical Trials Office (CTO)","800-811-8480","CTIP@VUMC.ORG",{"facility":199,"status":35,"city":200,"state":201,"zip":202,"country":39,"countryCode":40,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"SCRI at Mary Crowley","Dallas","Texas","75230",{"type":42,"coordinates":204},[205,206],-96.80667,32.78306,{"lat":206,"lon":205},[209],{"name":210,"role":28,"phone":211,"phoneExt":30,"email":212},"Angela Hotchkiss","214-658-1958","ahotchkiss@marycrowley.org",{"facility":214,"status":35,"city":215,"state":30,"zip":30,"country":216,"countryCode":217,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"University College London Hospital","London","United Kingdom","UK",{"type":42,"coordinates":219},[220,221],-0.12574,51.50853,{"lat":221,"lon":220},[224],{"name":225,"role":28,"phone":30,"phoneExt":30,"email":226},"UCLH Referrals","uclh.referrals.clinicalresearchfacility@nhs.net",{"type":228,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100555709","phase-1-a-phase-1-study-of-ctim-76-in-patients-with-recurring-ovarian-cancer-and-other-advanced-solid-tumors-100555709",false,"NCT06515613","A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors","A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors","Inclusion Criteria:\n\n* Participants with CLDN6 positive platinum resistant\u002Frefractory ovarian, advanced testicular or advanced endometrial cancer.\n* Participants with measurable disease per RECIST 1.1.\n* ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.\n* Participants with adequate organ function.\n\nExclusion Criteria:\n\n* Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.\n* Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.\n* Concurrent participation in another investigational clinical trial.","ALL","18 Years",{"count":239,"type":240},156,"ESTIMATED","INTERVENTIONAL",[243],"PHASE1","This is a Phase 1a\u002F1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory\u002Fresistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).",[246,247,248],"Platinum-resistant Ovarian Cancer","Testicular Cancer","Endometrial Cancer","2026-06-15",{"date":251,"type":252},"2026-06-16","ACTUAL",{"date":254,"type":252},"2024-07-10",{"date":256,"type":240},"2028-12-31",{"name":5,"class":6},14]